Breast Cancer in Young Women

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (1 November 2019) | Viewed by 15689

Special Issue Editor


E-Mail Website
Guest Editor
1. Women’s College Research Institute, Women’s College Hospital, Toronto, ON M5S 1B2, Canada
2. Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada
3. Institute of Medical Science, University of Toronto, Toronto, ON M5S 1A8, Canada
Interests: breast cancer; ovarian cancer; BRCA1; BRCA2; cancer prevention; screening
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In the United States, approximately 4.4% of breast cancers are diagnosed in women younger than 40, and these cases account for 2.5% of breast cancer deaths. These statistics actually underestimate the impact of early-onset breast cancer, because of all women who die from breast cancer, 8.6% are diagnosed before age 40. Little is known about the etiology of this disease, as the incidence of breast cancer in individuals aged under 40 is stable for women worldwide, but the mortality rate varies widely. The proportion of young women who have a genetic predisposition to breast cancer may be 20% or greater.

The poor prognosis of women with early-onset breast cancer is reflected, to some extent, by the relatively high proportion of young women who present with distant metastases and relatively poor pathologic features; however, stage and grade do not tell the whole story. Breast cancer-related deaths in young women are largely restricted to ER-positive cases. It is of interest that ER status is not a favorable marker for prognosis for young women, and it is important to determine whether other prognostic markers are associated with poor outcomes in this subgroup of women, and, in particular, if they can be used to determine the need for chemotherapy. However, caution should be exercised if chemotherapy is to be with-held from young women on the basis of prognosis. Further, treatment of this condition in young women is complicated by the fact that they may wish to have children after treatment; this raises concerns about optimizing treatment and maintaining fertility at the same time considering the possible teratogenic and toxic effects of current treatments. In the current issue, we explore topics related to breast cancer occurring in women before age 40.

Dr. Steven Narod
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 1021 KiB  
Article
Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer
by Zerin Hyder, Elaine F. Harkness, Emma R. Woodward, Naomi L. Bowers, Marta Pereira, Andrew J. Wallace, Sacha J. Howell, Anthony Howell, Fiona Lalloo, William G. Newman, Miriam J. Smith and D Gareth Evans
Cancers 2020, 12(2), 378; https://doi.org/10.3390/cancers12020378 - 7 Feb 2020
Cited by 24 | Viewed by 4434
Abstract
Early age at diagnosis of breast cancer is a known risk factor for hereditary predisposition and some studies show a high risk of contralateral breast cancer in BRCA1 carriers diagnosed at very young ages. However, little is published on the risk of TP53 [...] Read more.
Early age at diagnosis of breast cancer is a known risk factor for hereditary predisposition and some studies show a high risk of contralateral breast cancer in BRCA1 carriers diagnosed at very young ages. However, little is published on the risk of TP53 carriers. 397 women with breast cancer diagnosed <36 years of age were obtained from three sources: (i) a population-based study of 283 women diagnosed sequentially from 1980–1997 in North-West England, (ii) referrals to the Genomic Medicine Department at St Mary’s Hospital from 1990–2018, and (iii) individuals from (i) and the Family History Clinic at Wythenshawe Hospital South Manchester who tested negative for pathogenic variants (PV) in all three genes. Sequencing of BRCA1, BRCA2, and TP53 genes was carried out alongside tests for copy number for PV on all referred women. Rates of contralateral breast cancer were censored at death, last assessment, or risk-reducing mastectomy. In total, 47 TP53, 218 BRCA1, and 132 BRCA2 PV carriers were identified with breast cancer diagnosed aged 35 years and under, as well as a representative sample of 261 not known to carry a PV in BRCA1, BRCA2, and TP53. Annual rates of contralateral breast cancer (and percentage of synchronous breast cancers) were TP53: 7.03% (4.3%), BRCA1: 3.57% (1.8%), and BRCA2: 2.63% (1.5%). In non-PV carriers, contralateral rates in isolated presumed/tested non-carrier cases with no family history were 0.56%, and for those with a family history, 0.69%. Contralateral breast cancer rates are substantial in TP53, BRCA1, and BRCA2 PV carriers diagnosed with breast cancer aged 35 and under. Women need to be advised to help make informed decisions on contralateral mastectomy, guided by life expectancy from their index tumor. Full article
(This article belongs to the Special Issue Breast Cancer in Young Women)
Show Figures

Figure 1

Review

Jump to: Research

16 pages, 830 KiB  
Review
Breast Cancer during Pregnancy—Current Paradigms, Paths to Explore
by Ayelet Alfasi and Irit Ben-Aharon
Cancers 2019, 11(11), 1669; https://doi.org/10.3390/cancers11111669 - 28 Oct 2019
Cited by 25 | Viewed by 10537
Abstract
Breast cancer is the most common form of malignancy in pregnant women. The prevalence of pregnancy-associated breast cancer (PABC) is up to 0.04% of pregnancies and is expected to rise in developed countries. PABC represents a unique clinical scenario which requires a delicate [...] Read more.
Breast cancer is the most common form of malignancy in pregnant women. The prevalence of pregnancy-associated breast cancer (PABC) is up to 0.04% of pregnancies and is expected to rise in developed countries. PABC represents a unique clinical scenario which requires a delicate balance of risks and benefits for both maternal and fetal well-being. Currently, there is paucity of data regarding the short- and long-term outcomes of in-utero exposure to anti-neoplastic agents. In general, when possible, treatment for PABC should follow the same guidelines as in non-pregnant patients. Surgery, including sentinel lymph node biopsy, is possible during all trimesters of pregnancy. Radiotherapy is contraindicated during pregnancy, although it might be considered in highly selected patients based on risk–benefit assessment. Evidence supports that administration of chemotherapy may be safe during the second and third trimesters, with cessation of treatment three weeks prior to expected delivery. Currently, hormonal therapy and anti-HER2 agents are contraindicated during pregnancy and should be postponed until after delivery. Prematurity is associated with worse neonatal and long-term outcomes, and thus should be avoided. While current data on the long-term effects of anti-neoplastic treatments are reassuring, grade of evidence is lacking, hence additional large prospective studies with long-term follow-up are essential to rule out any treatment-induced adverse effects. Full article
(This article belongs to the Special Issue Breast Cancer in Young Women)
Show Figures

Figure 1

Back to TopTop